Tangganjian decoction ameliorates type 2 diabetes mellitus and nonalcoholic fatty liver disease in rats by activating the IRS/PI3K/AKT signaling pathway
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
AIM Previous clinical studies have demonstrated that tangganjian (TGJ), a modern Chinese prescribed medicine, has a clinical effect in the treatment of type 2 diabetes mellitus (T2DM) with nonalcoholic fatty liver disease (NAFLD). Our study aimed to investigate whether the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway is involved in this therapeutic effect. MATERIALS AND METHODS T2DM and NAFLD rat models were constructed and treated with three different concentrations of TGJ. Pioglitazone was used as a positive control, along with the model and normal groups. For analyses, blood and livers were collected. Levels of glucose and lipid metabolism indicators, including fasting insulin and total cholesterol, were determined. The expression levels of insulin receptor substrate (IRS), PI3K, and AKT were also determined by western blotting and immunohistochemistry. Liver tissues were stained with hematoxylin & eosin. RESULTS In the high-dose TGJ-treated and positive groups, there was a significant increase in the HDL-C level and decreases in the levels of the fasting blood glucose, 2 h postprandial blood glucose, fasting insulin, triglyceride, total cholesterol, and low-density lipoprotein cholesterol, along with a significant increase in the expression of IRS, PI3K, and AKT in the liver. TGJ could also attenuate or counteract the effects of T2DM and NAFLD in the liver lobules. CONCLUSION A high concentration of TGJ can improve glucose and lipid metabolism by activating the IRS/PI3K/AKT signaling pathway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammatory pathways and insulin action
Hotamisligil, G. S. (2003) · International Journal of Obesity · doi:10.1038/sj.ijo.0802502 · Cited by 717
PDK1, one of the missing links in insulin signal transduction?1
Cohen, P., Alessi, D. R., & Cross, D. A. E. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00490-0 · Cited by 246
Cited by
Metaflammation in glucolipid metabolic disorders: Pathogenesis and treatment
Xiong, P., Zhang, F., Liu, F., Zhao, J., Huang, X., Luo, D., & Guo, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114545 · Cited by 59
Xie, X., Liao, J., Ai, Y., Gao, J., Zhao, J., Qu, F., Xu, C., Zhang, Z., Wen, W., Cui, H., et al. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.748872 · Cited by 37
Wang, M., Yang, F., Yan, X., Chao, X., Zhang, W., Yuan, C., & Zeng, Q. (2022) · Journal of Food Biochemistry · doi:10.1111/jfbc.14275 · Cited by 29
Metadata
- Authors
- Fan, Y., He, Z., Wang, W., Li, J., Hu, A., Li, L., Yan, L., Li, Z., & Yin, Q.
- Venue
- Biomedicine & Pharmacotherapy
- Publisher
- Elsevier BV
- Published
- 2018-10
- Volume
- 106
- Pages
- 733-737
- ISSN
- 0753-3322 (ISSN-L)
- OpenAlex
- W2839831244
- Cited by
- 54
- References
- 2
- FWCI
- 3.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tangganjian decoction ameliorates type 2 diabetes mellitus and nonalcoholic fatty liver disease in rats by activating the IRS/PI3K/AKT signaling pathway. https://app.cochat.ai/papers/10.1016/j.biopha.2018.06.089
- The paper
- Fan, Y., He, Z., Wang, W., Li, J., Hu, A., Li, L., Yan, L., Li, Z., & Yin, Q. (2018). Tangganjian decoction ameliorates type 2 diabetes mellitus and nonalcoholic fatty liver disease in rats by activating the IRS/PI3K/AKT signaling pathway. Biomedicine & Pharmacotherapy. https://doi.org/10.1016/j.biopha.2018.06.089
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.